The study medication should be stopped in participants who require dual antiplatelet therapy or anticoagulation for any indication, including acute coronary syndrome or need for percutaneous coronary intervention with stenting.
Standard antiplatelet therapy (including loading dose) can be administered according to usual practice. Standard anticoagulant therapy can be started anytime without regard to the timing of the most recent dose of the study medication.
For participants who do not require long-term dual antiplatelet therapy or anticoagulant, the study medication should be continued.
